These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26706104)

  • 21. Reply to Erik Rud, Peter Lauritzen, and Eduard Baco's Letter to the Editor re: Henrik Grönberg, Martin Eklund, Wolfgang Picker, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol 2018;74:722-8.
    Eklund M; Ström P; Grönberg H; Nordström T
    Eur Urol; 2019 Apr; 75(4):e104-e105. PubMed ID: 30514569
    [No Abstract]   [Full Text] [Related]  

  • 22. Re: Manfred Wirth, Nicola Fossati, Peter Albers, et al. The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. Eur Urol 2019;76:179-86.
    Wei Y; Zhang R; Ye L
    Eur Urol; 2020 Mar; 77(3):e75. PubMed ID: 31594706
    [No Abstract]   [Full Text] [Related]  

  • 23. Reply to Benjamin S. Simpson, Lina M. Carmona Echeverria, Joseph M. Norris, Hashim U. Ahmed, Caroline M. Moore, and Hayley C. Whitaker's Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol 2020;77:501-7.
    Chesnut GT; Vickers AJ; Ehdaie B
    Eur Urol; 2020 Sep; 78(3):e108-e109. PubMed ID: 32522388
    [No Abstract]   [Full Text] [Related]  

  • 24. Reply to Lu Yang, Shi Qiu and Qiang Wei's Letter to the Editor re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol 2016;69:775-87.
    Bayne CE; Williams -B; Chapin BF
    Eur Urol; 2017 Feb; 71(2):e51. PubMed ID: 27461403
    [No Abstract]   [Full Text] [Related]  

  • 25. Letter to the Editor; Re: Wirth MP, Weissbach L, Marx F-J, Heckl W, Jellinghaus W, Riedmiller H, Noack B, Hinke A, Froehner M. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004;45:267-70.
    Rocco B; Matei DV; de Cobelli O; Rocco F
    Eur Urol; 2004 Aug; 46(2):272-3; author reply 273. PubMed ID: 15245825
    [No Abstract]   [Full Text] [Related]  

  • 26. Reply to Leah Bensimon, Samy Suissa, and Laurent Azoulay's letter to the editor re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16.
    Spratt DE; Zhang Z; Zelefsky MJ
    Eur Urol; 2013 Aug; 64(2):e29-30. PubMed ID: 23619389
    [No Abstract]   [Full Text] [Related]  

  • 27. Reply to Francesco Montorsi and Giorgio Gandaglia's Letter to the Editor re: Riccardo Autorino, Homayoun Zagar, Mirandolino B. Mariano, et al. Perioperative Outcomes of Robotic and Laparoscopic Simple Prostatectomy: A European-American Multi-institutional Analysis. Eur Urol 2015;68:86-94; Re: Matthew Bultitude, Ben Challacombe. Simple Prostatectomy: A Step Too Far for Laparoscopy? Eur Urol 2015;68:95-6. Eur Urol 2015;68:e7-8.
    Autorino R; Zargar H; Porpiglia F
    Eur Urol; 2015 Jul; 68(1):e9-10. PubMed ID: 25666848
    [No Abstract]   [Full Text] [Related]  

  • 28. Reply to Laura Evangelista and Egesta Lopci's Letter to the Editor re: Hendrik Van Poppel, Renée Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. Eur Urol 2021;79:327-9: Early Detection of Prostate Cancer in High-risk Patients with Negative Fusion Biopsy.
    Van Poppel H; Hogenhout R; Albers P; van den Bergh RCN; Barentsz JO; Roobol MJ
    Eur Urol; 2021 Jul; 80(1):e28-e29. PubMed ID: 33965287
    [No Abstract]   [Full Text] [Related]  

  • 29. Reply to Ola Bratt and Anna Öfverholm's Letter to the Editor re: Peter Ström, Tobias Nordström, Henrik Grönberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.12.028.
    Eklund M; Ström P; Nordström T; Grönberg H
    Eur Urol; 2018 Jul; 74(1):e10-e11. PubMed ID: 29598984
    [No Abstract]   [Full Text] [Related]  

  • 30. Reply to Lars Egevad, Hemamali Samaratunga, John R. Srigley, Brett Delahunt's Letter to the Editor re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2016;70:1.
    Zietman A; Smith J; Klein E; Droller M; Dasgupta P; Catto J
    Eur Urol; 2017 Feb; 71(2):e54. PubMed ID: 27452952
    [No Abstract]   [Full Text] [Related]  

  • 31. Reply to Carsten Stephan, Henning Cammann, and Klaus Jung's Letter to the Editor re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039.
    Tomlins SA; Groskopf J; Chinnaiyan AM
    Eur Urol; 2015 Nov; 68(5):e108. PubMed ID: 26242717
    [No Abstract]   [Full Text] [Related]  

  • 32. Reply to the letter to the editor by Michael Froehner and Manfred Wirth on our article: "Socio-economic deprivation and cancer survival in Germany".
    Jansen L; Brenner H
    Int J Cancer; 2014 Oct; 135(8):1990. PubMed ID: 24604229
    [No Abstract]   [Full Text] [Related]  

  • 33. Reply to Yuxuan Song, Yiqing Du, and Tao Xu's Letter to the Editor re: Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
    Carvalho FLF; Mossanen M; Van Allen EM; Mouw KW
    Eur Urol; 2022 Nov; 82(5):e141-e142. PubMed ID: 35945087
    [No Abstract]   [Full Text] [Related]  

  • 34. Reply to Xiaoling Lin, Brian T. Helfand, and Jianfeng Xu's Letter to the Editor re: Daniel A. Leongamornlert, Edward J. Saunders, Sarah Wakerell, et al. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. Eur Urol 2019;76:329-37.
    Kote-Jarai Z; Leongamornlert DA; Saunders EJ; Conti DV; Eeles RA
    Eur Urol; 2019 Nov; 76(5):e130-e131. PubMed ID: 31235193
    [No Abstract]   [Full Text] [Related]  

  • 35. Reply to Vladimir Novotny, Manfred P. Wirth, Michael Froehner's letter to the editor re: Atiqullah Aziz, Matthias May, Maximilian Burger, et al. PROMETRICS 2011 research group. Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort. Eur Urol 2014;66:156-163.
    Roghmann F; May M; Aziz A
    Eur Urol; 2014 Jul; 66(1):e14. PubMed ID: 24598014
    [No Abstract]   [Full Text] [Related]  

  • 36. Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re: Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 2022;81:503-14. Improving the Methodological Quality of Prostate Cancer Core Outcome Sets in Future Updates.
    Beyer K; MacLennan S; Van Hemelrijck M
    Eur Urol; 2022 Sep; 82(3):e68-e69. PubMed ID: 35688663
    [No Abstract]   [Full Text] [Related]  

  • 37. Reply to Can Lu and Xiao Guan's Letter to the Editor re: Marko Babjuk. Are the Role of Surgery and its Complications Sufficiently Focused in the Era of Perioperative Systemic Treatments? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.01.022.
    Babjuk M
    Eur Urol; 2020 Aug; 78(2):e73-e74. PubMed ID: 32389446
    [No Abstract]   [Full Text] [Related]  

  • 38. Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
    de Bono J
    Eur Urol; 2017 Jan; 71(1):e11. PubMed ID: 27751730
    [No Abstract]   [Full Text] [Related]  

  • 39. Reply to Francesco Montorsi, Armando Stabile, Elio Mazzone, Giorgio Gandaglia, and Alberto Briganti's Letter to the Editor re: Deepika Reddy, Max Peters, Taimur T. Shah, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. Eur Urol 2022;81:407-13.
    Reddy D; Ahmed HU
    Eur Urol; 2022 Sep; 82(3):e74-e75. PubMed ID: 35690513
    [No Abstract]   [Full Text] [Related]  

  • 40. Reply to Weigang Yan, Zhien Zhou, Hanzhong Li's Letter to the Editor re: Jeffrey J. Tosoian, Debasish Sundi, Bruce J. Trock, et al. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. Eur Urol 2016;69:576-81.
    Tosoian JJ; Trock BJ; Ballentine Carter H; Mamawala M
    Eur Urol; 2017 Jan; 71(1):e13. PubMed ID: 27311363
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.